898.7500 11.40 (1.28%)
NSE Jun 27, 2025 15:31 PM
Volume: 668.4K
 

898.75
1.28%
ICICI Securities Limited
Strides Pharma Science’s (Strides) Q1FY24 earnings exhibited a healthy beat on margin front. Improved product mix, cost-optimisation initiatives and freight costs led to expansions in gross margin (+880bps YoY) and EBITDA margin (+1,250bps). Management aspires to improve from these levels going ahead. Adjusted for divested businesses, revenue recorded a healthy 11% YoY growth.
Strides Pharma Science Ltd. is trading below its 200 day SMA of 927.7
More from Strides Pharma Science Ltd.
Recommended